jueves, 4 de septiembre de 2025
CLINICAL PERSPECTIVES ++++++ ++++++
CLINICAL PERSPECTIVES
Evaluating Fenfluramine in Patients With Lennox-Gastaut Syndrome
https://checkrare.com/evaluating-fenfluramine-in-patients-with-lennox-gastaut-syndrome/
Amelie Lothe, PhD, Global Medical Community Head for Rare Epilepsies at UCB, discusses recent data evaluating fenfluramine in patients with Lennox-Gastaut syndrome.
Outpatient Administration of Naxitamab in Patients With Neuroblastoma
https://checkrare.com/outpatient-administration-of-naxitamab-in-patients-with-neuroblastoma/
Javier Oesterheld, MD, Division Chief of the Cancer and Blood Disorders Program at Levine Children’s Hospital and Founder and Executive Director of the ARISE Cancer Consortium, discusses outpatient administration of naxitamab in patients with neuroblastoma.
Recordati Rare Disease Initiatives
https://checkrare.com/recordati-rare-disease-initiatives/
Mohamed Ladha, President and General Manager for Recordati Rare Diseases North America, discusses the company’s rare disease initiatives.
Unmet Medical Needs in Rare Diseases
https://checkrare.com/unmet-medical-needs-in-rare-diseases/
Tobias Hagedorn, Secretary of the European Society for PKU (ESPKU), discusses unmet medical needs in rare disease communities.
Pre-Diagnostic Symptoms and Time-to-Diagnosis in MLD
https://checkrare.com/pre-diagnostic-symptoms-and-time-to-diagnosis-in-mld/
Laura Adang, MD, PhD, Assistant Professor at Perelman School of Medicine at University of Pennsylvania, discusses a cohort study conducted analyzing pre-diagnostic symptoms and time-to-diagnosis in patients with metachromatic leukodystrophy (MLD).
Symptom and Treatment Burden in Fabry Disease
https://checkrare.com/symptom-and-treatment-burden-in-fabry-disease/
Jack Johnson, Co-Founder and Executive Director of FSIG, discusses symptom and treatment burden in Fabry disease.
Positive Data on Fenfluramine for the Treatment of CDKL5 Deficiency Disorder
https://checkrare.com/positive-data-on-fenfluramine-for-the-treatment-of-cdkl5-deficiency-disorder/
Amélie Lothe, PhD, Head of Global Medical Community of Rare Epilepsies at UCB, discusses positive data on fenfluramine for the treatment of CDKL5 deficiency disorder (CDD).
Glioblastoma Overview
https://checkrare.com/glioblastoma-overview/
Erin Dunbar, MD, founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, discusses the current landscape of glioblastoma.
All Endpoints Met in Clinical Trials With Oveporexton for Narcolepsy
https://checkrare.com/all-endpoints-met-in-clinical-trials-with-oveporexton-for-narcolepsy/
Takeda has announced positive data from two phase 3 clinical trials of oveporexton in patients with narcolepsy type 1 (NT1).
Lumryz for Hallucinations in Patients With Narcolepsy
https://checkrare.com/lumryz-for-hallucinations-in-patients-with-narcolepsy/
Michael J. Thorpy, MD, Professor of Neurology at Albert Einstein College of Medicine, discusses positive results in study of Lumryz (sodium oxybate) for hallucinations in patients with narcolepsy.
Delpacibart Braxlosiran in Patients With Facioscapulohumeral Muscular Dystrophy
https://checkrare.com/delpacibart-braxlosiran-in-patients-with-facioscapulohumeral-muscular-dystrophy/
Mike Flanagan, PhD, Chief Scientific Officer at Avidity Biosciences, discusses topline results from study testing delpacibart braxlosiran (del-brax) in patients with facioscapulohumeral muscular dystrophy and the newly initiated phase 3 trial.
Implications of Nipocalimab Approval on Pediatric Patients With Myasthenia Gravis
https://checkrare.com/implications-of-nipocalimab-approval-on-pediatric-patients-with-myasthenia-gravis/
Jonathan Strober, MD, Director of the Neuromuscular Clinic and Professor of Pediatrics and Neurology at the University of California at San Francisco, discusses the implications of nipocalimab’s approval to treat pediatric patients with myasthenia gravis (MG).
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario